solfia.org
Response to Pegylated Interferon in Chronic Hepatitis B, Effect of with and without Precore Mutant Stain: A Multicenter Tunisian Study (GJGHV4N1A5) - synergy - synergy

Response to Pegylated Interferon in Chronic Hepatitis B, Effect of with and without Precore Mutant Stain: A Multicenter Tunisian Study Pages 18-23

Wafa Ben Mansour, Nabil Ben Chaabene, Wissem Melki, Mohamed Hichem Loghmari, Wided Bouhlel, Olfa Hellara, Fethia Bdioui, Leila Safer and Hamouda Saffar

Department of Hepatogastroenterology, Fattouma Bourguiba Hospital, Monastir, 5000, Tunisia

http://dx.doi.org/10.12970/2308-6483.2016.04.01.5

Abstract: Background and Study Aims: To evaluate the effectiveness of pegylated interferon in patients with chronic hepatitis B infection in a real life setting.

Patients and Methods: Fifteen hospitals in Tunisia were included in this study. Data from consecutively treated chronic hepatitis B (CHB) patients, who received pegylated interferon, were collected retrospectively. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Sustained virologic response (SVR) is defined as an hepatitis B virus (HBV) DNA concentration of less than 2,000 IU/mL six months after the completion of therapy.

Results: A total of 351 CHB patients under peg interferon alfa-2a treatment were included in this multicenter, open label, non-interventional study.

Thirty five HBeAg positive patients were identified (62% male, 23% advanced fibrosis). Six months after therapy, 24% had viral loads < 2000 IU/mL, 20% achieved HBeAg seroconversion and 5, 7% achieved HBs Ag loss.

Three hundreds sixteen HBeAg negative patients were treated (72, 5% male, 24% advanced fibrosis). Six months post-treatment, 14 % had viral loads < 2000 IU/mL and 1, 2% achieved HBs Ag loss.

Treatment was well tolerated in 92% of cases and was stopped in 5.2% of patients.

In multivariate analysis, predictors of response to pegylated interferon were: age less than 50 years (P=0,04 IC [0,169-0,737]), precore mutant stain infection (p=0,04 IC [0,60-0,69]), a body mass index < 30kg/m2 (P=0,05 IC [0,225-0,320]), and a pre-treatment serum HBV DNA level <20000IU/ml (P=0,03 IC [1,316-2,225]). Conclusion: PEG-IFN therapy in chronic hepatitis B (CHB) is well tolerated and can achieve a good response especially if we select good responders.

Keywords: Chronic hepatitis B, Treatment, pegylated interferon. Read more →

  • Why Choose Synergy

    Synergy Publishers opens a portal to researchers and scholarly communities We aspire to be one of the best publishers for professional and scholarly societies. We maintain a balanced, independent editorial policy being fully committed to authors with honesty. We strive to proceed in a manner that is conducive to a sustainable future.